IPSC

MKT CAP:$194M

Century Therapeutics, Inc.

Market Cap

$194M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.26+$1.27 (+127.16%)

Apr 23, 2026

Company Details

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced...

CEO

Brent Pfeiffenberger

IPO Date

Jun 18, 2021

Website

www.centurytx.com

Key Metrics TTM

Revenue

$109M

+1556.5% YoY

Net Income

-$10M

EPS (Diluted)

-$0.11

Free Cash Flow

-$105M

Revenue / Share

$1.26

Gross Margin

90.9%

Operating Margin

-13.8%

Net Margin

-8.8%

FCF Margin

-95.9%

P/S

1.8x

P/E

—

Earnings Reports

FY 2025

Mar 12, 2026

$109M+1556.8%EPS -$0.11

Q4 2025

Mar 12, 2026

$0-100.0%EPS -$0.22

Q3 2025

Nov 13, 2025

$0-100.0%EPS -$0.40

Q2 2025

Aug 14, 2025

$0-100.0%EPS -$0.38

Q1 2025

May 15, 2025

$109M+12667.7%EPS $0.89

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$1M	$1M	-$37M
Q2 22	$1M	$1M	-$31M
Q3 22	$2M	$2M	-$32M
Q4 22	$521.0K	-$3M	-$33M
Q1 23	$2M	-$450.0K	-$32M
Q2 23	$99.0K	$99.0K	-$35M
Q3 23	$148.0K	-$23M	-$36M
Q4 23	$268.0K	-$22M	-$44M
Q1 24	$855.0K	$855.0K	-$31M
Q2 24	$771.0K	$771.0K	-$35M
Q3 24	$791.0K	$791.0K	-$35M
Q4 24	$4M	$4M	-$37M
Q1 25	$109M	$109M	$74M
Q2 25	$0	-$3M	-$34M
Q3 25	$0	-$3M	-$29M
Q4 25	$0	-$4M	-$26M

Valuation

Quarter	P/S	P/E
Q1 22	675.7x	—
Q2 22	194.6x	—
Q3 22	125.2x	—
Q4 22	53.9x	—
Q1 23	34.8x	—
Q2 23	40.9x	—
Q3 23	45.5x	—
Q4 23	99.5x	—
Q1 24	242.7x	—
Q2 24	100.0x	—
Q3 24	50.1x	—
Q4 24	11.9x	—
Q1 25	0.4x	—
Q2 25	0.4x	—
Q3 25	0.4x	—
Q4 25	0.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$87M	$83M
Q2 22	-$26M	-$36M
Q3 22	-$24M	-$34M
Q4 22	-$23M	-$29M
Q1 23	-$29M	-$34M
Q2 23	-$19M	-$24M
Q3 23	-$14M	-$17M
Q4 23	-$26M	-$27M
Q1 24	-$30M	-$31M
Q2 24	-$27M	-$28M
Q3 24	-$28M	-$28M
Q4 24	-$24M	-$24M
Q1 25	-$35M	-$35M
Q2 25	-$28M	-$28M
Q3 25	-$26M	-$26M
Q4 25	-$16M	-$16M

Capital Expenditures

Quarter	CapEx
Q1 22	$4M
Q2 22	$10M
Q3 22	$10M
Q4 22	$6M
Q1 23	$5M
Q2 23	$5M
Q3 23	$3M
Q4 23	$980.0K
Q1 24	$539.0K
Q2 24	$265.0K
Q3 24	$804.0K
Q4 24	$154.0K
Q1 25	$0
Q2 25	$317.0K
Q3 25	$195.0K
Q4 25	$317.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+113.1%
Q2 22	—	+42.2%
Q3 22	—	+31.5%
Q4 22	—	+20.9%
Q1 23	+62.6%	-12.2%
Q2 23	-92.9%	+7.4%
Q3 23	-93.3%	+5.3%
Q4 23	-48.6%	+30.2%
Q1 24	-50.3%	-4.8%
Q2 24	+678.8%	+1.0%
Q3 24	+434.5%	-0.5%
Q4 24	+1457.1%	-5.8%
Q1 25	+12667.7%	+8.8%
Q2 25	-100.0%	-3.5%
Q3 25	-100.0%	-18.2%
Q4 25	-100.0%	-37.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	225.0%
Q2 22	$3M	198.5%
Q3 22	$3M	125.3%
Q4 22	$3M	524.4%
Q1 23	$4M	220.8%
Q2 23	$3M	3318.2%
Q3 23	$4M	2687.8%
Q4 23	$4M	1329.1%
Q1 24	$3M	375.1%
Q2 24	$4M	454.3%
Q3 24	$0	0.0%
Q4 24	$3M	63.7%
Q1 25	$2M	2.2%
Q2 25	$2M	—
Q3 25	$892.0K	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$21M	$7M	—
Q2 22	$24M	$8M	—
Q3 22	$26M	$8M	—
Q4 22	$26M	—	$5M
Q1 23	$25M	—	$7M
Q2 23	$23M	$8M	—
Q3 23	$27M	$9M	—
Q4 23	$23M	$9M	—
Q1 24	$23M	$9M	—
Q2 24	$27M	$8M	—
Q3 24	$27M	$8M	—
Q4 24	$29M	$8M	—
Q1 25	$27M	$8M	—
Q2 25	$24M	—	$7M
Q3 25	$19M	—	$7M
Q4 25	$20M	$955.0K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$126M	$235M	$361M
Q2 22	$113M	$266M	$379M
Q3 22	$111M	$245M	$356M
Q4 22	$84M	$231M	$315M
Q1 23	$87M	$165M	$251M
Q2 23	$64M	$92M	$156M
Q3 23	$55M	$114M	$170M
Q4 23	$47M	$125M	$173M
Q1 24	$47M	$145M	$192M
Q2 24	$41M	$155M	$196M
Q3 24	$53M	$146M	$198M
Q4 24	$58M	$131M	$189M
Q1 25	$52M	$113M	$165M
Q2 25	$57M	$99M	$156M
Q3 25	$56M	$77M	$133M
Q4 25	$62M	$55M	$117M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	57M	+4.7%	+4.1%
Q2 22	58M	+1.1%	+6.0%
Q3 22	58M	+0.5%	+6.4%
Q4 22	58M	+0.6%	+7.1%
Q1 23	59M	+0.5%	+2.7%
Q2 23	59M	+1.1%	+2.7%
Q3 23	59M	+0.3%	+2.5%
Q4 23	60M	+0.7%	+2.7%
Q1 24	62M	+4.0%	+6.3%
Q2 24	82M	+31.8%	+38.5%
Q3 24	85M	+3.2%	+42.5%
Q4 24	79M	-7.1%	+31.3%
Q1 25	86M	+9.5%	+38.2%
Q2 25	86M	+0.2%	+5.1%
Q3 25	86M	+0.3%	+2.1%
Q4 25	87M	+0.1%	+10.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$5.6K	188
Q2 22	$7.4K	188
Q3 22	$11.8K	188
Q4 22	$2.8K	184
Q1 23	$9.3K	184
Q2 23	$538	184
Q3 23	$804	184
Q4 23	$1.6K	165
Q1 24	$5.2K	165
Q2 24	$4.7K	165
Q3 24	$4.8K	165
Q4 24	$29.8K	140
Q1 25	$779.7K	140
Q2 25	$0	140
Q3 25	$0	140
Q4 25	$0	78

Revenue / Employee